Critical effects of long non-coding RNA on fibrosis diseases

Exp Mol Med. 2018 Jan 19;50(1):e428. doi: 10.1038/emm.2017.223.

Abstract

The expression or dysfunction of long non-coding RNAs (lncRNAs) is closely related to various hereditary diseases, autoimmune diseases, metabolic diseases and tumors. LncRNAs were also recently recognized as functional regulators of fibrosis, which is a secondary process in many of these diseases and a primary pathology in fibrosis diseases. We review the latest findings on lncRNAs in fibrosis diseases of the liver, myocardium, kidney, lung and peritoneum. We also discuss the potential of disease-related lncRNAs as therapeutic targets for the clinical treatment of human fibrosis diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alu Elements
  • Animals
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p57 / genetics
  • Fibrosis / genetics*
  • Fibrosis / metabolism
  • Fibrosis / pathology
  • Humans
  • Kidney / pathology
  • Liver / pathology
  • Lung / pathology
  • Myocardial Infarction / genetics
  • Myocardial Infarction / pathology
  • Myocardium / pathology
  • RNA, Long Noncoding* / genetics
  • Rats

Substances

  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclin-Dependent Kinase Inhibitor p57
  • MEG3 non-coding RNA, human
  • RNA, Long Noncoding